Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

ClinicalTrials.gov ID: NCT00998686

Public ClinicalTrials.gov record NCT00998686. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 3:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Active-Controlled, Multi-Center Extension Study to Evaluate Safety and Efficacy of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to demonstrate the safety and tolerability of dutogliptin over 52 weeks.

Study identification

NCT ID
NCT00998686
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Phenomix
Industry
Enrollment
650 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2009
Primary completion
Sep 30, 2011
Completion
Oct 31, 2011
Last update posted
Aug 10, 2010

2009 – 2011

United States locations

U.S. sites
23
U.S. states
16
U.S. cities
21
Facility City State ZIP Site status
Phenomix Investigational Site 105 Montgomery Alabama
Phenomix Investigational Site 121 Tempe Arizona
Phenomix Investigational Site 137 Tempe Arizona
Phenomix Investigational Site 105 Anaheim California
Phenomix Investigational Site 103 Long Beach California
Phenomix Investigational Site 106 Los Angeles California
Phenomix Investigational Site 143 Coral Gables Florida
Phenomix Investigational Site 142 Hialeah Florida
Phenomix Investigational Site 133 Kissimmee Florida
Phenomix Investigational Site 101 Honolulu Hawaii
Phenomix Investigational Site 135 Chicago Illinois
Phenomix Investigational Site 124 Indianapolis Indiana
Phenomix Investigational Site 136 Brockton Massachusetts
Phenomix Investigational Site 138 Biloxi Mississippi
Phenomix Investigational Site 122 Las Vegas Nevada
Phenomix Investigational Site 140 Las Vegas Nevada
Phenomix Investigational Site 110 Trenton New Jersey
Phenomix Investigational Site 116 Albuquerque New Mexico
Phenomix Investigational Site 107 Winston-Salem North Carolina
Phenomix Investigational Site 112 Greenville South Carolina
Phenomix Investigational Site 102 Dallas Texas
Phenomix Investigational Site 104 San Antonio Texas
Phenomix Investigational Site 100 Kenosha Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00998686, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 10, 2010 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00998686 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →